Buyback alert! Last date to buy Aurobindo Pharma shares for Rs 800-crore share buyback. Check details

Investors looking to participate in Aurobindo Pharma‘s share buyback worth Rs 800 crore will likely have to purchase the shares of the company latest by today, April 16, before the stock goes ex-record date for the corporate action tomorrow.

The pharma company on April 6 had announced a share buyback, with the price fixed at Rs 1,475 apiece, implying a premium of more than 7% from the Wednesday’s closing price of Rs 1,374 apiece. The record date to determine the eligibility of shareholders for the corporate action was set at April 17.

This means that the shares of the company must be credited to the demat accounts of the shareholders by April 17 in order to be eligible for the buyback. As per the T+1 settlement rule, today will mark the last day to buy the shares of the company, so that the shares are credited by April 17.

Aurobindo Pharma will buy back 54.24 lakh shares as part of the corporate action, representing 0.93% stake in the company. It will utilise 2.62% of its free reserves, including securities premium, the company had said. The repurchase will be carried out through the tender offer route. This marks the company’s second buyback in less than two years.

Buyback of shares refers to a corporate action where a company repurchases its own shares from the existing shareholders. Usually, the company purchases the shares at a higher price than the current levels, encouraging investors to participate. Typically, a company decides to buy back its shares in order to increase share value, utilise surplus cash, prevent hostile takeovers or to increase promoter holdings. Aurobindo Pharma had announced its first buyback of shares worth Rs 750 crore in 2024.

Aurobindo Pharma’s promoters and promoter groups held nearly 52% stake in the company, according to data on its shareholding pattern as on December 31, 2025. Mutual funds held nearly 20% stake while insurance companies held 5.5% stake. Foreign investors held around 14% stake while the general public and others held nearly 8% stake in the company at the end of last year.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)